Brief: Karyopharm Therapeutics Q3 Net Income USD -32.072 Million
05/11/2024 12:30
Nov 05 (Reuters) - Karyopharm Therapeutics Q3 operating expenses USD 65.066 million. * Q3 operating income USD -26.283 million * Q3 product revenue USD 29.516 million * outlook FY revenue USD 145-155 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview